Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer
OBJECTIVES: I. Compare the efficacy of leucovorin calcium plus fluorouracil with either
irinotecan or oxaliplatin in terms of progression free survival in patients with recurrent
metastatic colorectal cancer. II. Compare the efficacy, tolerance, quality of life, and
overall survival in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating
institution and measurable or evaluable disease. Patients are randomized to receive either a
2 hour continuous infusion of irinotecan or a 2 hour continuous infusion of oxaliplatin on
day 1. All patients receive a 2 hour continuous infusion of leucovorin calcium followed by
IV bolus and 48 hour continuous infusion of fluorouracil on days 1 and 2. Courses are
repeated every 2 weeks. Patients will receive the alternate treatment if disease progression
or unacceptable toxicity occurs on their initial treatment. Patients are followed every 3
months after end of treatment.
PROJECTED ACCRUAL: This study will accrue a total of 109 patients per arm over approximately
18 months.
Interventional
Allocation: Randomized, Primary Purpose: Treatment
Aimery de Gramont, MD
Study Chair
Hopital Saint Antoine
United States: Federal Government
CDR0000066151
NCT00003260
January 1998
Name | Location |
---|